 Home > Active Ingredient News > Study of Nervous System > Intellia announces latest clinical follow-up data, in vivo CRISPR gene editing therapy has made further progress

Intellia announces latest clinical follow-up data, in vivo CRISPR gene editing therapy has made further progress

 Last Update: 2022-09-09
 Source: Internet
 Author: User

Tags

alpha 1 drugs

cellular cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

August 28, 2022 / eMedClub News / -- Intellia Therapeutics and Regeneron Pharma Announce Phase 1 of their In vivo Genome Editing Candidate NTLA-2001 Single Dose for the Treatment of Transthyretin (ATTR) Amyloidosis Interim data from the experimental trial

ATTR is a hereditary, progressively debilitating and fatal disease caused by mutations in the TTR gene

NTLA-2001, as an in vivo gene editing therapy for ATTR amyloidosis, opens up a whole new treatment modality for patients

References:

0yn5FjF2K8sIlXfIy4tgn3H75XcKyZPvHI*FREvVuTr&new=1

——List of recent popular activities——

▼August 29, Phase 2: Immunometabolism Analysis, Helping Cellular Immunotherapy

▼August 30, technical application and safety quality control of virus clearance research

▼August 31, new technology for membrane protein target development

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium bromide airuike

CAS No.: 7647-15-6

Industrial Grade

$10/KG EXW

Brivaracetam357336-20-0

CAS No.: 357336-20-0

API Grade

$100/KG EXW

Quetiapine fumarate CAS 111974-72-2

CAS No.: 111974-72-2

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.